A New Era for Eye Care? Valitor Aims for Twice-Yearly Wet AMD Treatment

BERKELEY, CA – May 04, 2026 – For millions of people living with wet age-related macular degeneration (AMD), life is often measured in weeks—the time between frequent, uncomfortable injections directly into the eye needed to preserve their vision. Biotechnology company Valitor is now aiming to change that calendar. The company today unveiled promising preclinical data for a new therapy, VLTR-559, that could potentially reduce this demanding treatment schedule to just two injections per year.

The data, presented at the prestigious Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting, suggests that VLTR-559 is not only effective but also exceptionally durable, a combination that could transform the standard of care for this leading cause of blindness in older adults.

“We continue to be encouraged by the superior durability, efficacy and safety profile of VLTR-559 observed in preclinical models for the treatment of wet AMD,” said Gregory D. Kunst, chief executive officer of Valitor, in a statement. “These latest data... further reinforce the potential of VLTR-559 to transform the treatment landscape of wet-AMD, as a single dose to induce and sustain efficacy for more than six-months and meaningfully reduce the treatment burden for patients.”

The Burden of the Needle

Wet AMD is a chronic, progressive disease where abnormal blood vessels grow under the retina, leaking fluid that damages light-sensitive cells and causes rapid vision loss. The advent of anti-vascular endothelial growth factor (anti-VEGF) therapies like Lucentis, Eylea, and the more recent Vabysmo revolutionized treatment, turning what was once a near-certain path to blindness into a manageable condition.

However, this victory comes at a cost. The effectiveness of these drugs wanes, requiring patients to return to their ophthalmologist’s office for intravitreal injections every one to four months. This relentless cycle imposes a significant burden. Patients often experience anxiety and discomfort, while the logistics of frequent appointments—travel, time off work, and reliance on caregivers—can be exhausting.

The healthcare system also feels the strain, with retinal specialists managing a high volume of procedures. While newer drugs have pushed the boundaries to allow for 12- or even 16-week intervals in some patients, the goal of a truly long-acting, reliable therapy has remained elusive. A treatment that could safely and effectively last for six months would represent a monumental leap forward, dramatically improving quality of life and potentially increasing treatment adherence, which is crucial for long-term vision preservation.

A New Paradigm in Drug Delivery

Valitor’s confidence in a six-month dosing schedule stems from the unique properties of VLTR-559, which is engineered using the company's proprietary multivalent polymer (MVP) technology platform. This technology is designed to create more stable, longer-lasting biologic drugs.

The data presented at ARVO provides a compelling early look at its potential. In preclinical studies, VLTR-559 demonstrated a vitreous half-life—a measure of how long half the drug remains in the eye's jelly-like interior—of 12 days. This is substantially longer than the 3-to-5-day half-life of conventional anti-VEGF biologics.

More importantly, this extended presence translated into sustained activity. The therapy’s anti-VEGF potency remained unchanged for up to 76 days after a single administration, showing it could persist in the target tissues of the retina without losing its power. This durability was achieved with a favorable safety profile; the studies showed no signs of elevated intraocular pressure or inflammation, which are key safety concerns for any new intraocular therapy. Together, these results form the foundation of Valitor's plan for a twice-yearly treatment.

Navigating a Crowded and Lucrative Market

Valitor is entering a fiercely competitive and highly valuable space. The global market for wet AMD treatments was valued at over $10 billion in 2025 and is projected to grow significantly as the global population ages. This massive market has attracted a wave of innovation, with numerous companies vying to solve the treatment burden problem.

The competitive landscape is diverse. On one end are surgically implanted solutions, such as the Port Delivery System that provides a continuous release of ranibizumab and requires refills every six months. On the other, more futuristic end, is gene therapy. Companies like Regenxbio and 4D Molecular Therapeutics are in late-stage trials for treatments designed to enable the eye to produce its own anti-VEGF protein, potentially offering a one-time fix. For example, the gene therapy Ixo-vec showed in Phase 3 trials that over half of patients needed no supplemental injections in the year following treatment.

VLTR-559 aims to carve out a powerful niche between these approaches. It offers the convenience of a six-month interval, matching that of a surgical implant, but with the familiarity and lower barrier to entry of a standard intravitreal injection. For patients and physicians who may be hesitant to embrace surgery or the permanence of gene therapy, a highly durable, injectable biologic could be the ideal solution.

The Road to the Clinic

Despite the exciting preclinical results, VLTR-559 is still in the early stages of its journey. The company is currently conducting IND-enabling activities, the necessary research and documentation required to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA).

Valitor has stated it plans to advance the therapy into human clinical evaluation next year. These upcoming clinical trials will be the true test, determining if the remarkable durability and safety seen in preclinical models can be replicated in human patients. The ophthalmology world will be watching closely as Valitor attempts to move from a promising concept to a revolutionary new standard of care for millions.